Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Renal ultrasound

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    286 result(s) found for: Renal ultrasound. Displaying page 7 of 15.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2021-000676-11 Sponsor Protocol Number: URO-901-3007 Start Date*: 2022-12-30
    Sponsor Name:Urovant Sciences GmbH
    Full Title: A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age with...
    Medical condition: Neurogenic Detrusor Overactivity (NDO)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10029279 Neurogenic bladder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Trial now transitioned) SK (Trial now transitioned) NO (Prematurely Ended) LV (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) PL (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003205-66 Sponsor Protocol Number: MedOPP293 Start Date*: 2022-01-17
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2)
    Medical condition: HER2-Positive Early Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) IT (Trial now transitioned) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002826-97 Sponsor Protocol Number: DCR-PHXC-204 Start Date*: 2021-01-29
    Sponsor Name:Dicerna Pharmaceuticals Inc
    Full Title: A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without Dialysis
    Medical condition: Primary Hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Not Authorised) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003492-29 Sponsor Protocol Number: 391402 Start Date*: 2016-03-02
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase 1/2a, Open-Label, Parallel, Two-Arm, Dose-Escalation Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BAX69 in Subjects with Refractory Ovarian...
    Medical condition: Refractory Ovarian Cancer with Malignant Ascites
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021430-64 Sponsor Protocol Number: RR10/9389 Start Date*: 2010-12-03
    Sponsor Name:University of Leeds
    Full Title: A randomised double blind placebo controlled clinical trial of anti B-cell therapy in patients with primary Sjögren’s syndrome.
    Medical condition: Primary Sjögren’s syndrome (PSS).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021718-41 Sponsor Protocol Number: 214868-004-03 Start Date*: 2011-03-03
    Sponsor Name:Allergan Ltd
    Full Title: A Pilot, Multicenter, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety and Efficacy of AGN-214868 in Patients with Idiopathic Overactive Bladder and Urinary Incontinence
    Medical condition: To evaluate the safety and efficacy of AGN-214868 compared with placebo in the treatment of patients with idiopathic overactive bladder (IOAB) and urinary incontinence.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-006532-21 Sponsor Protocol Number: 40054-22062 Start Date*: 2008-10-27
    Sponsor Name:EORTC
    Full Title: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6)
    Medical condition: locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004461-47 Sponsor Protocol Number: DV3-MEL-01[SYNERGY-001] Start Date*: 2017-07-10
    Sponsor Name:Dynavax Technologies Corporation
    Full Title: A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastati...
    Medical condition: Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000436-27 Sponsor Protocol Number: BR3031 Start Date*: 2007-02-16
    Sponsor Name:University of Birmingham [...]
    1. University of Birmingham
    2. University Hospital Birmingham NHS Foundation Trust
    Full Title: Neoadjuvant trial of pre-operative exemestane or letrozole +/-celecoxib in the treatment of ER positive postmenopausal early breast cancer.
    Medical condition: Postmenopausal early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-002918-41 Sponsor Protocol Number: IJB-EBC-Decrescendo-2020 Start Date*: 2021-08-25
    Sponsor Name:Institut Jules Bordet
    Full Title: De-Escalation of neoadjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chem...
    Medical condition: HER2-positive, estrogen receptor (ER)-negative/progesterone receptor (PR)-negative, node-negative early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) IT (Prematurely Ended) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000770-29 Sponsor Protocol Number: Ireland-RctV8 Start Date*: 2018-06-18
    Sponsor Name:The Rotunda Hospital
    Full Title: Investigating the role of early low-dose aspirin in diabetes: A phase III multicentre double-blinded placebo-controlled randomised trial of low-dose aspirin initiated in the first trimester of diab...
    Medical condition: Pregestational type I or type II diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045228 Type I diabetes mellitus LLT
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001983-49 Sponsor Protocol Number: UX023-CL205 Start Date*: 2019-10-10
    Sponsor Name:Ultragenyx Pharmaceutical Inc
    Full Title: An Open-Label, Phase 2 Study to Assess the Safety, Pharmacodynamics, and Efficacy of KRN23 in Children from 1 to 4 Years Old with X-linked Hypophosphatemia (XLH)
    Medical condition: XLH is a disorder of hypophosphatemia, renal phosphate wasting, and the most common inheritable form of rickets. In XLH patients, excess circulating fibroblast growth factor (FGF23) impair phosphat...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10016206 Familial hypophosphataemic rickets LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-002538-20 Sponsor Protocol Number: EORTC 62027 Start Date*: 2006-02-24
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Phase 2 study of Glivec (Imatinib) in locally advanced and/or metastatic soft tissue sarcomas expressing the t(17;22)(q22;q13) translocation resulting in a COL1A1/PDGF rearrangement i.e. DermatoFib...
    Medical condition: Soft tissue sarcomas are a family of malignant diseases originating from mesenchymal cells. Two types of theses sarcomas, dermatofibrosarcoma protuberans (DFSP) and giant cell fibriblastoma(GCF), a...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10057070 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000138-12 Sponsor Protocol Number: ALADIN2 Start Date*: 2011-04-04
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A prospective, randomized, double-blind, placebo controlled clinical trial to assess the effects of long-acting somatostatin (Octreotide LAR)therapy on disease progression in patients with Autosoma...
    Medical condition: Autosomal Dominant Polycystic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001938-14 Sponsor Protocol Number: 60711868 Start Date*: 2008-03-31
    Sponsor Name:AVAPO RICERCHE - VENEZIA
    Full Title: Neoadjuvant docetaxel, cisplatin and 5-fluororacil (TPF) followed by radiotherapy plus concomitant chemotherapy or cetuximab versus radiotherapy plus concomitant chemotherapy or cetuximab in patien...
    Medical condition: patients with locally advanced squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002322-11 Sponsor Protocol Number: ARTemis Start Date*: 2009-04-29
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust [...]
    1. Cambridge University Hospitals NHS Foundation Trust
    2. University of Cambridge
    Full Title: ARTemis : Avastin® Randomised Trial with nEo-adjuvant cheMotherapy for patients wIth early breaSt cancer
    Medical condition: HER2 negative invasive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002836-97 Sponsor Protocol Number: 240193 Start Date*: 2012-12-20
    Sponsor Name:Tartu University Hospital
    Full Title: Pharmacokinetics of penicillin, ampicillin and gentamicin in near- term and full-term neonates
    Medical condition: neonatal sepsis, pneumonia and meningitis
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000318-24 Sponsor Protocol Number: RH-ITA-006 Start Date*: 2016-08-30
    Sponsor Name:Dept. of Intensive Care 4131, Copenhagen University Hospital Rigshospitalet
    Full Title: Stress Ulcer Prophylaxis in the Intensive Care Unit
    Medical condition: Prophylaxis of stress related gastrointestinal bleeding among critically ill patients in the intensive care unit.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10042613 - Surgical and medical procedures 10022519 Intensive care PT
    19.1 100000004856 10071910 Upper gastrointestinal bleeding LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) FI (Completed) NO (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005086-70 Sponsor Protocol Number: SHP602-206 Start Date*: 2015-09-11
    Sponsor Name:SHIRE DEVELOPMENT LLC AND INTERNATIONAL AFFILIATES
    Full Title: A Multicenter Study to Monitor for the Potential Development of Renal Tumors in Subjects With Transfusional Iron Overload Who Were Previously Exposed to Deferitazole
    Medical condition: n patients with B-thalassemia, regular transfusions are not only essential to maintain acceptable hemoglobin levels for treatment of the underlying anemia but also to suppress endogenous erythropoi...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10065974 Chronic iron overload LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000222-35 Sponsor Protocol Number: 2017-000222-35 Start Date*: 2017-07-21
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients – a randomized controlled trial
    Medical condition: Secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 15 08:01:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA